Download

Free Med Pocket Cards

Diabetes Medication PocketCard eUpdates

We have two updates to announce that have been captured in our electronic Medication PocketCards.

Saxagliptin Discontinued

The DPP-IV Inhibitor Saxagliptin (Onglyza) and combination medication, Kombiglyze XR (saxagliptin/metformin extended-release tablets), have been permanently discontinued, according to manufacturer AstraZeneca.

A recent posting on the Food and Drug Administration’s (FDA) Drug Shortages tracker indicates that both products were discontinued because of a business decision and not due to safety or efficacy-related concerns.

There are three other DPP-IV inhibitors still available along with several combination versions. See our updated electronic ePocketCard that reflects this update.

Dulaglutide Approved for Peds

In late 2022, the FDA approved the use of Dulaglutide (Trulicity for Pediatrics with Type 2 diabetes ages 10-17. Currently, metformin, insulin and the following GLP-1 RA’s are approved for pediatrics with type 2 diabetes, ages 10-17 See updated ePocketCard.

GLP-1 RA list of approved medications for pediatrics.

  • Exenatide XR (Bydureon)
  • Liraglutide (Victoza)
  • Dulaglutide (Trulicity) up to 1.5mgs

GLP-1 RAs have the benefit of not only lowering A1C, they also support weight loss and Exenatide XR and dulaglutide only need to be taken once a week. This weekly dosing can be a big advantage for busy families.

Our currently available laminated Diabetes Med PocketCards do not reflect these changes, but we will be reprinting later this year to reflect these updates.


Download our FREE CDCES Coach App

Access to our latest pocketcards, cheat sheets, and other free resources right in your pocket. Download our CDCES Coach App!


Starting your journey to becoming a CDCES? Our FREE Webinar

Preparing for the CDCES Exam

Airs live on Thursday, July 13th at 11:30 am PST

This course will transform your test anxiety into calm self-confidence and test-taking readiness.

Preparing for the CDCES Exam Webinar Topics

  • Exam requirement updates for 2023.
  • Exam eligibility and test format
  • Strategies to succeed along with a review of study tips and test-taking tactics.
  • We will review sample test questions and the reasoning behind choosing the right answers.
  • Learn how to focus your time and prepare to take the CDCES Exam. We provide plenty of sample test questions and test-taking tips!
Can’t join us live?
Don’t worry, we will send you a link to the recorded version.

Becoming a Certified Diabetes Care and Education Specialist (CDCES) is one of the best professional and personal decisions I have ever made.” – Coach Beverly Thomassian, RN, MPH, CDCES, BC-ADM

 


 

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

Sign up for DiabetesEd Blog Bytes

* indicates required

 

 



The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.

Sign up for Diabetes Blog Bytes!

We post weekly Blog Bytes that are informative and FREE! Every week we post one exam practice Question of the Week and Rationale of the Week. Sign up below!

Form Heading

The use of DES products does not guarantee the successful passage of the certification exam. CBDCE and ADCES do not endorse any preparatory or review materials for the CDCES or BC-ADM exams, except for those published by CBDCE & ADCES.

**To satisfy the requirement for renewal of certification by continuing education for the Certification Board for Diabetes Care & Education (CBDCE), continuing education activities must be applicable to diabetes and approved by a provider on the CBDCE List of Recognized Providers (www.cbdce.org). CBDCE does not approve continuing education. Diabetes Education Services is accredited/approved by the Commission of Dietetic Registration which is on the list of CBDCE Recognized Providers.

Recent Blog Bytes